These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

196 related items for PubMed ID: 10219982

  • 1. Human CRF2 alpha and beta splice variants: pharmacological characterization using radioligand binding and a luciferase gene expression assay.
    Ardati A, Goetschy V, Gottowick J, Henriot S, Valdenaire O, Deuschle U, Kilpatrick GJ.
    Neuropharmacology; 1999 Mar; 38(3):441-8. PubMed ID: 10219982
    [Abstract] [Full Text] [Related]

  • 2. 125I-Tyro-sauvagine: a novel high affinity radioligand for the pharmacological and biochemical study of human corticotropin-releasing factor 2 alpha receptors.
    Grigoriadis DE, Liu XJ, Vaughn J, Palmer SF, True CD, Vale WW, Ling N, De Souza EB.
    Mol Pharmacol; 1996 Sep; 50(3):679-86. PubMed ID: 8794910
    [Abstract] [Full Text] [Related]

  • 3. Autoradiographic localization of CRF1 and CRF2 binding sites in adult rat brain.
    Primus RJ, Yevich E, Baltazar C, Gallager DW.
    Neuropsychopharmacology; 1997 Nov; 17(5):308-16. PubMed ID: 9348546
    [Abstract] [Full Text] [Related]

  • 4. Characterization of [125I]sauvagine binding to CRH2 receptors: membrane homogenate and autoradiographic studies.
    Rominger DH, Rominger CM, Fitzgerald LW, Grzanna R, Largent BL, Zaczek R.
    J Pharmacol Exp Ther; 1998 Jul; 286(1):459-68. PubMed ID: 9655891
    [Abstract] [Full Text] [Related]

  • 5. Distribution of corticotropin-releasing factor (CRF) receptor binding in the mouse brain using a new, high-affinity radioligand, [125 I]-PD-Sauvagine.
    Tan LA, Vaughan JM, Perrin MH, Rivier JE, Sawchenko PE.
    J Comp Neurol; 2017 Dec 15; 525(18):3840-3864. PubMed ID: 28842924
    [Abstract] [Full Text] [Related]

  • 6. Structure and function of the ovine type 1 corticotropin releasing factor receptor (CRF1) and a carboxyl-terminal variant.
    Myers DA, Trinh JV, Myers TR.
    Mol Cell Endocrinol; 1998 Sep 25; 144(1-2):21-35. PubMed ID: 9863624
    [Abstract] [Full Text] [Related]

  • 7. Recent advances with the CRF1 receptor: design of small molecule inhibitors, receptor subtypes and clinical indications.
    McCarthy JR, Heinrichs SC, Grigoriadis DE.
    Curr Pharm Des; 1999 May 25; 5(5):289-315. PubMed ID: 10213797
    [Abstract] [Full Text] [Related]

  • 8. Labelling of CRF1 and CRF2 receptors using the novel radioligand, [3H]-urocortin.
    Gottowik J, Goetschy V, Henriot S, Kitas E, Fluhman B, Clerc RG, Moreau JL, Monsma FJ, Kilpatrick GJ.
    Neuropharmacology; 1997 Oct 25; 36(10):1439-46. PubMed ID: 9423932
    [Abstract] [Full Text] [Related]

  • 9. Expression and characterisation of human and rat CRF2alpha receptors.
    Suman-Chauhan N, Carnell P, Franks R, Webdale L, Gee NS, McNulty S, Rossant CJ, Van Leeuwen D, MacKenzie R, Hall MD.
    Eur J Pharmacol; 1999 Aug 27; 379(2-3):219-27. PubMed ID: 10497909
    [Abstract] [Full Text] [Related]

  • 10. Development of a selective photoactivatable antagonist for corticotropin-releasing factor receptor, type 2 (CRF2).
    Bonk I, Rühmann A.
    Eur J Biochem; 2002 Nov 27; 269(21):5288-94. PubMed ID: 12392562
    [Abstract] [Full Text] [Related]

  • 11. Peptide ligand binding properties of the corticotropin-releasing factor (CRF) type 2 receptor: pharmacology of endogenously expressed receptors, G-protein-coupling sensitivity and determinants of CRF2 receptor selectivity.
    Hoare SR, Sullivan SK, Fan J, Khongsaly K, Grigoriadis DE.
    Peptides; 2005 Mar 27; 26(3):457-70. PubMed ID: 15652653
    [Abstract] [Full Text] [Related]

  • 12. Evidence for the abundant expression of arginine 185 containing human CRF(2alpha) receptors and the role of position 185 for receptor-ligand selectivity.
    Dautzenberg FM, Huber G, Higelin J, Py-Lang G, Kilpatrick GJ.
    Neuropharmacology; 2000 Jun 08; 39(8):1368-76. PubMed ID: 10818253
    [Abstract] [Full Text] [Related]

  • 13. Autoradiographic and in situ hybridization localization of corticotropin-releasing factor 1 and 2 receptors in nonhuman primate brain.
    Sánchez MM, Young LJ, Plotsky PM, Insel TR.
    J Comp Neurol; 1999 Jun 07; 408(3):365-77. PubMed ID: 10340512
    [Abstract] [Full Text] [Related]

  • 14. The ligand-selective domains of corticotropin-releasing factor type 1 and type 2 receptor reside in different extracellular domains: generation of chimeric receptors with a novel ligand-selective profile.
    Dautzenberg FM, Kilpatrick GJ, Wille S, Hauger RL.
    J Neurochem; 1999 Aug 07; 73(2):821-9. PubMed ID: 10428081
    [Abstract] [Full Text] [Related]

  • 15. Functional, endogenously expressed corticotropin-releasing factor receptor type 1 (CRF1) and CRF1 receptor mRNA expression in human neuroblastoma SH-SY5Y cells.
    Schoeffter P, Feuerbach D, Bobirnac I, Gazi L, Longato R.
    Fundam Clin Pharmacol; 1999 Aug 07; 13(4):484-9. PubMed ID: 10456290
    [Abstract] [Full Text] [Related]

  • 16. Characterisation using microphysiometry of CRF receptor pharmacology.
    Smart D, Coppell A, Rossant C, Hall M, McKnight AT.
    Eur J Pharmacol; 1999 Aug 27; 379(2-3):229-35. PubMed ID: 10497910
    [Abstract] [Full Text] [Related]

  • 17. Conformational states of the corticotropin releasing factor 1 (CRF1) receptor: detection, and pharmacological evaluation by peptide ligands.
    Hoare SR, Sullivan SK, Pahuja A, Ling N, Crowe PD, Grigoriadis DE.
    Peptides; 2003 Dec 27; 24(12):1881-97. PubMed ID: 15127940
    [Abstract] [Full Text] [Related]

  • 18. Different binding modes of amphibian and human corticotropin-releasing factor type 1 and type 2 receptors: evidence for evolutionary differences.
    Dautzenberg FM, Py-Lang G, Higelin J, Fischer C, Wright MB, Huber G.
    J Pharmacol Exp Ther; 2001 Jan 27; 296(1):113-20. PubMed ID: 11123370
    [Abstract] [Full Text] [Related]

  • 19. [¹²⁵I]YP20: a novel radioligand specific for the extracellular domain of the CRF₁ receptor.
    Gordon JC, Edwards P, Elmore CS, Lazor LA, Paschetto K, Bostwick R, Sylvester M, Mauger R, Scott C, Aharony D.
    Eur J Pharmacol; 2010 Dec 15; 649(1-3):59-63. PubMed ID: 20854803
    [Abstract] [Full Text] [Related]

  • 20. Characterization of a Pachymedusa dacnicolor-Sauvagine analog as a new high-affinity radioligand for corticotropin-releasing factor receptor studies.
    Perrin MH, Tan LA, Vaughan JM, Lewis KA, Donaldson CJ, Miller C, Erchegyi J, Rivier JE, Sawchenko PE.
    J Pharmacol Exp Ther; 2015 May 15; 353(2):307-17. PubMed ID: 25736419
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.